Idioma:

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

Ikeda, M. ; Shimizu, S. ; Sato, T. ; Morimoto, M. ; Kojima, Y. ; Inaba, Y. ; Hagihara, A. ; Kudo, M. ; Nakamori, S. ; Kaneko, S. ; Sugimoto, R. ; Tahara, T. ; Ohmura, T. ; Yasui, K. ; Sato, K. ; Ishii, H. ; Furuse, J. ; Okusaka, T.

Annals of oncology, 2016-11, Vol.27 (11), p.2090-2096 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
Autor: Ikeda, M. ; Shimizu, S. ; Sato, T. ; Morimoto, M. ; Kojima, Y. ; Inaba, Y. ; Hagihara, A. ; Kudo, M. ; Nakamori, S. ; Kaneko, S. ; Sugimoto, R. ; Tahara, T. ; Ohmura, T. ; Yasui, K. ; Sato, K. ; Ishii, H. ; Furuse, J. ; Okusaka, T.
Assuntos: Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - pathology ; cisplatin ; Cisplatin - administration & dosage ; Disease-Free Survival ; Female ; hepatic arterial infusion chemotherapy ; hepatocellular carcinoma ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Male ; Middle Aged ; Neoplasm Staging ; Niacinamide - administration & dosage ; Niacinamide - analogs & derivatives ; Original ; Phenylurea Compounds - administration & dosage ; randomized phase II trial ; Sorafenib ; Treatment Outcome
É parte de: Annals of oncology, 2016-11, Vol.27 (11), p.2090-2096
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
Descrição: Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC. We conducted a multicenter open-labeled randomized phase II trial in chemo-naïve patients with advanced HCC with Child-Pugh scores of 5–7. Eligible patients were randomly assigned 2:1 to receive SorCDDP (sorafenib: 400mg bid; cisplatin: 65mg/m2, day 1, every 4–6 weeks) or Sor (400mg bid). The primary end point was overall survival. A total of 108 patients were randomized (Sor, n = 42; SorCDDP, n = 66). The median survival in the Sor and SorCDDP arms were 8.7 and 10.6 months, respectively [stratified hazard ratio (95% confidence interval), 0.60 (0.38–0.96), P = 0.031]. The median time to progression and the response rate were, respectively, 2.8 months and 7.3% in the Sor arm and 3.1 months and 21.7% in the SorCDDP arm. The adverse events were more frequent in the SorCDDP arm than in the Sor arm, but well-tolerated. SorCDDP yielded favorable overall survival when compared with Sor in patients with advanced HCC. UMIN-CTR (http://www.umin.ac.jp/ctr/index-j.htm), identification number: UMIN000005703.
Editor: England: Elsevier Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 3 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

Ikeda, M. ; Shimizu, S. ; Sato, T. ; Morimoto, M. ; Kojima, Y. ; Inaba, Y. ; Hagihara, A. ; Kudo, M. ; Nakamori, S. ; Kaneko, S. ; Sugimoto, R. ; Tahara, T. ; Ohmura, T. ; Yasui, K. ; Sato, K. ; Ishii, H. ; Furuse, J. ; Okusaka, T.

England: Elsevier Ltd

Buscando em bases de dados remotas. Favor aguardar.